- Home
- AVIR vs LXEO Comparison
AVIR vs LXEO Comparison
Compare AVIR & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVIR | LXEO |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.5M | 368.3M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AVIR | LXEO |
|---|---|---|
| Price | $4.89 | $4.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $10.00 | ★ $18.44 |
| AVG Volume (30 Days) | 330.7K | ★ 962.8K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $3.60 |
| 52 Week High | $6.45 | $10.99 |
Technical Indicators
Market Signals| Indicator | AVIR | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 49.74 |
| Support Level | $4.14 | $4.44 |
| Resistance Level | $6.37 | $5.34 |
| Average True Range (ATR) | 0.21 | 0.31 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 82.72 | 45.54 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.